Control of cellular events in urothelial tumours

Aims and objectives of this presentation
In this session, miRNA and long coding RNA in urothelial cancer will be highlighted. Their involvement in oncogenic and tumour suppressive regulation of carcinogenesis will be presented. The session will also focus on innovative therapy applications in this malignancy.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*283 Intravesical instillation of exogenous microRNA-145 as a therapy for mouse orthotopic human bladder cancer xenograft
By: Inamoto T.¹, Taniguchi K.², Takahara K.¹, Iwatsuki A.², Takai T.¹, Komura K.¹, Yoshikawa Y.¹, Uchimoto T.¹, Saito K.¹, Tanda N.¹, Kouno J.¹, Minami K.¹, Uehara H.¹, Hirano H.¹, Nomi H.¹, Kiyama S.¹, Akao Y.², Azuma H.³
Institutes: ¹Osaka Medical College, Dept. of Urology, Osaka, Japan, ²Gifu University, United Graduate School of Drug Discovery and Medical Information Sciences, Gifu, Japan

*284 Intravesical delivery of hydrophobic drug using mucoadhesive cationic serum albumin nanoparticle as a carrier for bladder cancer therapy
By: Chiong E.¹, Lu S.², Tan C.³, Rahmat J.³, Kang E.T.², Mahendran R.³, Neoh K.G.²
Institutes: ¹National University Health System, Dept. of Urology, Singapore, Singapore, ²National University of Singapore, Dept. of Engineering, Singapore, Singapore, ³National University of Singapore, Dept. of Surgery, Singapore, Singapore

*285 MRNA expression levels and prognostic value of PD1/PDL1 and CTLA4 pathways genes in a large series of 155 bladder tumours
By: Le Goux C.¹, Bieche I.¹, Barry De Longchamps N.², Vacher S.¹, Sibony M.³, Zerbib M.², Damotte D.³, Pignot G.⁴
Institutes: ¹Institut Curie, Dept. of Pharmacogenomicque, Paris, France, ²Hopital Cochin, Dept. of Urology, Paris, France, ³Hopital Cochin, Dept. of Anatomopathology, Paris, France, ⁴Institut Paoli-Calmettes, Dept. of Urology, Marseille, France

*286 Long noncoding RNAs in bladder cancer. Expression and quantification of MALAT1 in low and high risk tumours
By: Virseda Rodriguez A.J.¹, Garcia Hernandez J.L.³, Garcia Garcia J.¹, Salvatierra Perez C.¹, Núñez Otero J.¹, Coderque Mejia M.P.¹, Hernandez Sanchez T.¹, Hernandez Rivas J.M.², Herrero Polo M.¹, Martin Parada A.¹, Cruz J.J.³, Gómez Veiga F.¹
Institutes: ¹Salamanca University Hospital, Dept. of Urology IBSAL-GITUR, Salamanca, Spain, ²Cancer Investigation Center of University of Salamanca, IBMCC, Salamanca, Spain, ³Research Unit of The University Hospital of Salamanca, Salamanca, Spain, ⁴Cancer Research (CIC-IBSMCC;CSIC/USAL; IBSAL), Salamanca, Spain, ⁵Novel and Hospitalar Salamanca’s Complex, Dept. of Oncology, Salamanca, Spain

*287 Targeting protein kinase CK2 suppresses bladder cancer cell survival via glycolysis pathway
By: Tao T., Zhang X., Yang C., Cheng Y., Li P., Yang X., Deng X., Lu Q.
**Poster Session 23**

**Is two protein immunohistochemistry assay able to identify the basal subtype of bladder cancer?**

**Institutes:** Hôpitaux Universitaires Henri Mondor, Dept. of Urology, Créteil, France, IRMB, Translational Research In Genito- Urinary Cancers, Créteil, France, Ligue Nationale Contre Le Cancer, Carte D'identité des Tumeurs Program, Paris, France, Foch Hospital, Dept. of Urology, Suresnes, France, INSERM, INSERM U946, Paris, France, Ramon Y Cajal Hospital, Dept. of Oncology, Madrid, Spain, CNIO, Genetic and Molecular Epidemiology Group, Madrid, Spain, CNIO, Epithelial Carcinogenesis Group, Madrid, Spain, CNRIS, Instituts Curie, UMR 144, Paris, France, Henri Mondor Hospital, Dept. of Pathology, Créteil, France, Henri Mondor Hospital, Dept. of Urology, Créteil, France

**Sulfated hyaluronic acid: A novel antitumor agent for bladder cancer**
By: Hennig M., Jordan A., Chipollini J., Hupe M., Kramer M., Lopez L., Merseburger A., Lokeshwar V.

**Institutes:** University of Lübeck, Dept. of Urology, Lübeck, Germany, Sylvester Comprehensive Cancer Center, University of Miami - Miller School of Medicine, Dept. of Urology, Miami, United States of America, University of Miami - Miller School of Medicine, Dept. of Urology, Miami, United States of America, Medical College of Georgia, Augusta University, Dept. of Biochemistry & Molecular Biology, Augusta, United States of America

**Topical and systemic immunoreaction induced by intravesical instillation of chemotherapeutic agents in a BBN-induced bladder cancer mouse model**

**Institutes:** Nara Medical University, Dept. of Urology, Nara, Japan

**Efficacy of recombinant bacille Calmette-Guérin secreting interleukin-15 against bladder cancer**
By: Takeuchi A., Tatsugami K., Shiotani M., Yokomizo A., Inokuchi J., Kashiwagi E., Takashi D., Eto M.

**Institutes:** Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan

**Circulating tumour cells in patients with advanced urothelial carcinoma of the bladder and correlation with tumour stage, lymph node metastases and FDG-PET-findings**

**Institutes:** UCL Cancer Institute, Dept. of Cancer Biology, London, United Kingdom, UCL Medical School, Dept. of Surgery & Interventional Science, London, United Kingdom, UCL Cancer Institute, Dept. of Cancer Biology, London, United Kingdom, CIEMAT, Molecular Oncology Unit, Madrid, Spain, UCL Cancer Institute, Dept. of Cancer Biology, London, United Kingdom, University College London Hospital, Dept. of Histopathology, London, United Kingdom, University of Birmingham, School of Cancer Sciences, London, United Kingdom

**UroMark - a highly multiplex biomarker for the detection of bladder cancer**

**Institutes:** UCL Cancer Institute, Dept. of Cancer Biology, London, United Kingdom, UCL Medical School, Dept. of Surgery & Interventional Science, London, United Kingdom, UCL Cancer Institute, Dept. of Cancer Biology, London, United Kingdom, CIEMAT, Molecular Oncology Unit, Madrid, Spain, UCL Cancer Institute, Dept. of Cancer Biology, London, United Kingdom, University College London Hospital, Dept. of Histopathology, London, United Kingdom, University of Birmingham, School of Cancer Sciences, London, United Kingdom

**Hormonal receptor and Her2 status correlates independently of gender with staging and grading in non muscle-invasive urothelial bladder carcinoma**
Poster Session 23

Institutes: 1University of Regensburg, Dept. of Urology, Regensburg, Germany, 2Stratifyer Molecular Pathology, Dept. of Pathology, Cologne, Germany, 3University of Mannheim, Dept. of Urology, Mannheim, Germany, 4University of Erlangen-Nuremberg, Institute of Pathology, Erlangen, Germany